A Novel CD73 Inhibitor SHR170008 Suppresses Adenosine in Tumor and Enhances Anti-Tumor Activity with PD-1 Blockade in a Mouse Model of Breast Cancer.

Suxing LiuDi LiJian LiuHuiyun WangIvana HorecnyRu ShenRumin ZhangHeping WuQiyue HuPeng ZhaoFengqi ZhangYinfa YanJun FengLinghang ZhuangJing LiLianshan ZhangWeikang Tao

Published in: OncoTargets and therapy (2021)

Our findings suggest that CD73 may serve as an immune checkpoint by generating adenosine, which suppresses the antitumor activity of anti-PD-1 mAb, and inhibition of CD73 may be a potential beneficial combination partner with immune-checkpoint inhibitors to improve their therapeutic outcomes in general.

Keyphrases

mouse model
signaling pathway
nk cells
type diabetes
protein kinase
risk assessment
skeletal muscle
climate change
insulin resistance
hiv infected
monoclonal antibody